{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T02:44:52Z","timestamp":1775270692091,"version":"3.50.1"},"reference-count":44,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Guangzhou Basic and Applied Foundation Project","award":["2023A04J1106"],"award-info":[{"award-number":["2023A04J1106"]}]},{"name":"Real World Research Project Grant Fund from the Hainan Institute of Real World data","award":["HNLC2022RWS018"],"award-info":[{"award-number":["HNLC2022RWS018"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant number 82273732"],"award-info":[{"award-number":["Grant number 82273732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Stat Methods Med Res"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hybrid clinical trial design integrates traditional randomized controlled trials (RCTs) with real-world data (RWD), aiming to enhance trial efficiency through dynamic incorporation of external data (External trial data and RWD). However, existing methods, such as the Meta-Analytic Predictive (MAP) Prior, exhibit serious limitations in controlling data heterogeneity, adjusting baseline discrepancies, and optimizing dynamic borrowing proportions. These limitations often introduce external bias or compromise evidence reliability, hindering their application in complex analyses like bridging trials and multi-regional clinical trials (MRCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study proposes a novel hybrid Bayesian framework, EQPS Robust MAP (rMAP), to address heterogeneity and bias in multi-source data integration. Its feasibility and robustness are validated through systematic simulations and retrospective case analyses, using two independent datasets to evaluate the effect of Risankizumab in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Methods<\/jats:title>\n                    <jats:p>The EQPS-rMAP method operates in three stages: (1) Eliminating baseline covariate discrepancies through propensity score stratification; (2) constructing stratum-specific MAP priors to dynamically adjust weights for external data; and (3) introducing equivalence probability weights to quantify data conflict risks. The study evaluates the method's performance across six simulated analyses (heterogeneity differences, baseline shifts, etc.), comparing it with traditional methods (MAP, PSMAP, Empirical Bayes MAP) in terms of estimation bias, type I error control, and sample size requirements. Real-world case analyses further validate its applicability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Simulations demonstrate that EQPS-rMAP maintains estimation robustness under considerable heterogeneity while reducing sample size demands and enhancing trial efficiency. Case analyses confirm its ability to control external bias while preserving high estimation accuracy compared to conventional approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The EQPS-rMAP method provides empirical evidence for the feasibility of hybrid clinical designs. Its methodological advancements\u2014resolving baseline and heterogeneity conflicts through adaptive mechanisms\u2014offer broader applicability for integrating external and RWD across diverse analyses, including bridging trials, MRCTs, and post-marketing studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09622802251414586","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:35:37Z","timestamp":1770399337000},"page":"552-570","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A hybrid prior Bayesian method for combining domestic real-world data and overseas data in global drug development"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1756-2030","authenticated-orcid":false,"given":"Keer","family":"Chen","sequence":"first","affiliation":[{"name":"Southern Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9533-5617","authenticated-orcid":false,"given":"Zengyue","family":"Zheng","sequence":"additional","affiliation":[{"name":"Southern Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"MSD China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuping","family":"Jiang","sequence":"additional","affiliation":[{"name":"MSD China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"MSD R&D (China) Co., Ltd"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumin","family":"Deng","sequence":"additional","affiliation":[{"name":"Southern Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingyan","family":"Chen","sequence":"additional","affiliation":[{"name":"The Administration of Boao Lecheng International Medical Tourism Pilot Zone"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Public Health, Fudan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-4552","authenticated-orcid":false,"given":"Ying","family":"Wu","sequence":"additional","affiliation":[{"name":"Southern Medical University"},{"name":"The Administration of Boao Lecheng International Medical Tourism Pilot Zone"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"U.S. Food and Drug Administration. Complex innovative trial design meeting program. 2022 https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/complex-innovative-trial-design-meeting-program."},{"key":"e_1_3_3_3_2","unstructured":"U.S. Food and Drug Administration. ACT EU multi-annual workplan 2022\u20132026. 2022 https:\/\/www.ema.europa.eu\/en\/documents\/other\/act-eu-multi-annual-workplan-2022-2026_en.pdf."},{"key":"e_1_3_3_4_2","first-page":"31790","article-title":"Guidance on ethnic factors in the acceptability of foreign clinical data; availability\u2014FDA","volume":"63","author":"International Conference on Harmonisation","year":"1998","unstructured":"International Conference on Harmonisation. Guidance on ethnic factors in the acceptability of foreign clinical data; availability\u2014FDA. Fed Regist 1998; 63: 31790\u201331796.","journal-title":"Fed Regist"},{"key":"e_1_3_3_5_2","first-page":"345","article-title":"Statistical methods for bridging studies in new drug clinical trials","volume":"32","author":"Liu J","year":"2015","unstructured":"Liu J, Yu H, Bai J, et\u00a0al. Statistical methods for bridging studies in new drug clinical trials. Chin J Health Stat 2015; 32: 345\u2013349.","journal-title":"Chin J Health Stat"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1177"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-120014567"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-120014564"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-200062284"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2012.701580"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2012.702651"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-200040836"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-120024210"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543400601001501"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1009212673"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2012.698436"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/env.752"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1214\/12-BA722"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12242"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8970"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2016.1226324"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2315"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1740774509356002"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2088"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3782"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1555"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.9.4.403"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1984.10478078"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.2307\/2528036"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cjs.5550340302"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1983.tb01251.x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2019.1657133"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9095"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/03610928908830127"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/25.3-4.285"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxy009"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18010"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.283"},{"key":"e_1_3_3_40_2","unstructured":"U.S. Food and Drug Administration. Using Bayesian statistical approaches to evaluate drug products. 2023 https:\/\/www.fda.gov\/drugs\/cder-small-business-industry-assistance-sbia\/using-bayesian-statistical-approaches-advance-our-ability-evaluate-drug-products."},{"key":"e_1_3_3_41_2","unstructured":"U.S. Food and Drug Administration. Advancing the use of complex innovative designs in clinical trials: From pilot to practice. 2024 https:\/\/www.fda.gov\/news-events\/advancing-use-complex-innovative-designs-clinical-trials-pilot-practice-03052024."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.179430"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-120037180"},{"key":"e_1_3_3_44_2","unstructured":"U.S. Food and Drug Administration. Rare diseases: Common issues in drug development \u2013 Draft guidance for industry. 2019 https:\/\/www.fda.gov\/media\/119757\/download."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510061"}],"container-title":["Statistical Methods in Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09622802251414586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09622802251414586","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09622802251414586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:46:57Z","timestamp":1775267217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09622802251414586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/09622802251414586"],"URL":"https:\/\/doi.org\/10.1177\/09622802251414586","relation":{},"ISSN":["0962-2802","1477-0334"],"issn-type":[{"value":"0962-2802","type":"print"},{"value":"1477-0334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}